×
About 13,372 results
Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

Global Initiative for Asthma: Global Strategy for Asthma Management & Prevention
https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

Sep 29th, 2019 - The 2019 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one of the most common chronic lung diseases worldwide contains extensive citations from the scientifi...

Can Mild Asthma Be Managed with Only As-Needed Inhaled Steroids Plus a Bronchodilator?
https://www.jwatch.org/na49830/2019/09/26/can-mild-asthma-be-managed-with-only-needed-inhaled

Sep 25th, 2019 - David J. Amrol, MD reviewing Hardy J et al. Lancet 2019 Sep 14 Gauthier M and Wenzel SE. Lancet 2019 Sep 14

Are Antihistamines and Steroids Helpful for Anaphylaxis?
https://www.jwatch.org/na49921/2019/09/24/are-antihistamines-and-steroids-helpful-anaphylaxis

Sep 23rd, 2019 - David J. Amrol, MD reviewing Gabrielli S et al. J Allergy Clin Immunol Pract 2019 Sep/Oct

FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
http://ir.aimmune.com/news-releases/news-release-details/fda-allergenic-products-advisory-committee-votes-support-use

Sep 12th, 2019 - Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy. PALFORZIA is a comp...

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/

Sep 11th, 2019 - GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US.

Scientists discover immune cell subtype in mice that drives allergic reactions
https://www.nih.gov/news-events/news-releases/scientists-discover-immune-cell-subtype-mice-drives-allergic-reactions

Jul 31st, 2019 - Allergies can be life-threatening when they cause anaphylaxis, an extreme reaction with constriction of the airways and a sudden drop in blood pressure. Scientists have identified a subtype of immune cell that drives the production of antibodies (link is external) associated with anaphylaxis and other allergic reactions. The research was funded by the National Institute of Allergy and Infectio...

Clinical trial to evaluate experimental treatment in people allergic to multiple foods
https://www.nih.gov/news-events/news-releases/clinical-trial-evaluate-experimental-treatment-people-allergic-multiple-foods

Jul 31st, 2019 - Though food allergy affects more than 4.8 million children in the United States, no approved preventative treatments currently exist. While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidenta...

Risk of Acute Myocardial Infarction and Ischemic Stroke in Patients with Asthma Exacerbation: A Population-Based, Self-Controlled Case Series Study
https://www.sciencedirect.com/science/article/abs/pii/S2213219819306178?via%3Dihub
The Journal of Allergy and Clinical Immunology: In Practice; Raita, Y. et. al.

Jul 15th, 2019 - Background Patients with asthma have a high incidence of acute myocardial infarction and ischemic stroke. Objective To investigate the acute effect of asthma exacerbation on these cardiovascular events. Methods Using population-based inpatient data of 3 geographically diverse US states (Florida, Nebraska, and New York) during the period 2011 to 2014, we conducted a self-controlled case...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
https://tevapharm.com/news/teva_announces_fda_approval_of_airduo_sup_reg_sup_digihaler_trade_fluticasone_propionate_113_mcg_and_salmeterol_14_mcg_inhalation_powder_07_19.aspx

Jul 14th, 2019 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma....

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is used to treat primary immunodeficiencies.

Clinical Trials | NUCALA (mepolizumab)
https://gskpro.com/en-us/products/nucala/for-severe-eosinophilic-asthma/efficacy/

Jun 26th, 2019 - NUCALA (mepolizumab) has clinical data on exacerbation reduction. Learn about NUCALA for patients with severe eosinophilic asthma.

Atopic dermatitis/Eczema | DermNet NZ
https://www.dermnetnz.org/topics/atopic-dermatitis/

Jun 24th, 2019 - Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema and was formerly known as Besnier prurigo. It is the most common form of dermatitis. Atopic dermatitis usually occurs in people who have an 'atopic tendency'. This means they may develop any or all of three closely linked conditions; atop...

Eczema - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK538209/
Nemeth, V. et. al.

Jun 3rd, 2019 - Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the "itch that rashes" due to dry skin that lea...

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013024.pub2/full
The Cochrane Database of Systematic Reviews; Threapleton, C. et. al.

May 23rd, 2019 - Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial load and inflammation in the airways. Studies have shown a reduction of exacerbations with antibiotics in comparison to placebo in people with COPD, ...

Rate of life-threatening childbirth complications increasing sharply across U.S. racial, ethnic groups
https://www.nih.gov/news-events/news-releases/rate-life-threatening-childbirth-complications-increasing-sharply-across-us-racial-ethnic-groups

May 2nd, 2019 - Racial and ethnic disparities in severe maternal morbidity — life-threatening maternal complications associated with childbirth — have persisted and increased at high rates among U.S. women, according to an analysis of nearly 20 years of California hospital records funded by the National Institutes of Health. Known risk factors for these complications — such as blood pressure disorders, asthma ...

Interventions for hand eczema
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004055.pub2/full
The Cochrane Database of Systematic Reviews; Christoffers, W. et. al.

Apr 25th, 2019 - Hand eczema is an inflammation of the skin of the hands that tends to run a chronic, relapsing course. This common condition is often associated with itch, social stigma, and impairment in employment. Many different interventions of unknown effectiveness are used to treat hand eczema.

Asthma Data, Statistics, and Surveillance
https://www.cdc.gov/asthma/asthmadata.htm

Mar 24th, 2019 - The latest national and state data on the burden of asthma among children and adults.

The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing...
https://doi.org/10.1542/peds.2019-0281

Mar 17th, 2019 - This clinical report updates and replaces a 2008 clinical report from the American Academy of Pediatrics, which addressed the roles of maternal and early infant diet on the prevention of atopic disease, including atopic dermatitis, asthma, and food allergy. As with the previous report, the available data still limit the ability to draw firm conclusions about various aspects of atopy prevention ...